Antimycobacterial Therapy in Crohn's Disease: Game Over?

Gastroenterology

Volumn 132, Issue 7, 2007, Pages 2594-2598

  Peyrin Biroulet, Laurent ^a   Neut, Christel ^a   Colombel, Jean Frédéric ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CLOFAZIMINE; ISONIAZID; PLACEBO; PREDNISOLONE; PYRAZINAMIDE; PYRIMETHAMINE; RIFABUTIN; SULFADOXINE;

ANTIMICROBIAL THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG MEGADOSE; DRUG WITHDRAWAL; EDITORIAL; HUMAN; MAINTENANCE THERAPY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM AVIUM; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; TREATMENT OUTCOME;

EID: 34250022162     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.04.027     Document Type: Editorial

References (48)

1. Dalziel T.K. Chronic intestinal enteritis. BMJ 2 (1913) 1068-1070
2. Chiodini R.J. Crohn's disease and the mycobacterioses: a review and comparison of two disease entities. Clin Microbiol Rev 2 (1989) 90-117
3. Millar D., Ford J., Sanderson J., Withey S., Tizard M., Doran T., and Hermon-Taylor J. IS900 PCR to detect Mycobacterium paratuberculosis in retail supplies of whole pasteurized cows' milk in England and Wales. Appl Environ Microbiol 62 (1996) 3446-3452
4. Mishina D., Katsel P., Brown S.T., Gilberts E.C., and Greenstein R.J. On the etiology of Crohn disease. Proc Natl Acad Sci U S A 93 (1996) 9816-9820
5. Abubakar I., Myhill D.J., Hart A.R., Lake I.R., Harvey I., Rhodes J.M., Robinson R., Lobo A.J., Probert C.S., and Hunter P.R. A case-control study of drinking water and dairy products in Crohn's disease-further investigation of the possible role of Mycobacterium avium paratuberculosis. Am J Epidemiol 165 (2007) 776-783
6. Autschbach F., Eisold S., Hinz U., Zinser S., Linnebacher M., Giese T., Loffler T., Buchler M.W., and Schmidt J. High prevalence of Mycobacterium avium subspecies paratuberculosis IS900 DNA in gut tissues from individuals with Crohn's disease. Gut 54 (2005) 944-949
7. Sechi L.A., Scanu A.M., Molicotti P., Cannas S., Mura M., Dettori G., Fadda G., and Zanetti S. Detection and Isolation of Mycobacterium avium subspecies paratuberculosis from intestinal mucosal biopsies of patients with and without Crohn's disease in Sardinia. Am J Gastroenterol 100 (2005) 1529-1536
8. Naser S.A., Ghobrial G., Romero C., and Valentine J.F. Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet 364 (2004) 1039-1044
9. Sartor R.B. Does Mycobacterium avium subspecies paratuberculosis cause Crohn's disease?. Gut 54 (2005) 896-898
10. Thiam S., LeFevre A.M., Hane F., Ndiaye A., Ba F., Fielding K.L., Ndir M., and Lienhardt C. Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA 297 (2007) 380-386
11. Fujikane T., Fujiuchi S., Yamazaki Y., Sato M., Yamamoto Y., Takeda A., Nishigaki Y., Fujita Y., and Shimizu T. Efficacy and outcomes of clarithromycin treatment for pulmonary MAC disease. Int J Tuberc Lung Dis 9 (2005) 1281-1287
12. Afdhal N.H., Long A., Lennon J., Crowe J., and O'Donoghue D.P. Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. Dig Dis Sci 36 (1991) 449-453
13. Basilisco G., Ranzi T., Campamini M.C., et al. Controlled trial of rifabutin in Crohn's disease. Curr Therapeut Res 46 (1989) 245-260
14. Borody T.J., Leis S., Warren E.F., and Surace R. Treatment of severe Crohn's disease using antimycobacterial triple therapy-approaching a cure?. Dig Liver Dis 34 (2002) 29-38
15. Elliott P.R., Burnham W.R., Berghouse L.M., Lennard-Jones J.E., and Langman M.J. Sulphadoxine-pyrimethamine therapy in Crohn's disease. Digestion 23 (1982) 132-134
16. Goodgame R.W., Kimball K., Akram S., Ike E., Ou C.N., Sutton F., and Graham D. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Aliment Pharmacol Ther 15 (2001) 1861-1866
17. Gui G.P., Thomas P.R., Tizard M.L., Lake J., Sanderson J.D., and Hermon-Taylor J. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J Antimicrob Chemother 39 (1997) 393-400
18. Hampson S.J., Parker M.C., Saverymuttu S.H., Joseph A.E., McFadden J.J., and Hermon-Taylor J. Quadruple antimycobacterial chemotherapy in Crohn's disease: results at 9 months of a pilot study in 20 patients. Aliment Pharmacol Ther 3 (1989) 343-352
19. Leiper K., Morris A.I., and Rhodes J.M. Open label trial of oral clarithromycin in active Crohn's disease. Aliment Pharmacol Ther 14 (2000) 801-806
20. Prantera C., Bothamley G., Levenstein S., Mangiarotti R., and Argentieri R. Crohn's disease and mycobacteria: two cases of Crohn's disease with high anti-mycobacterial antibody levels cured by dapsone therapy. Biomed Pharmacother 43 (1989) 295-299
21. Prantera C., Kohn A., Mangiarotti R., Andreoli A., and Luzi C. Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 89 (1994) 513-518
22. Rutgeerts P., Geboes K., Vantrappen G., Van Isveldt J., Peeters M., Penninckx F., and Hiele M. Rifabutin and ethambutol do not help recurrent Crohn's disease in the neoterminal ileum. J Clin Gastroenterol 15 (1992) 24-28
23. Shaffer J.L., Hughes S., Linaker B.D., Baker R.D., and Turnberg L.A. Controlled trial of rifampicin and ethambutol in Crohn's disease. Gut 25 (1984) 203-205
24. Shafran I., Kugler L., El-Zaatari F.A., Naser S.A., and Sandoval J. Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig Liver Dis 34 (2002) 22-28
25. Swift G.L., Srivastava E.D., Stone R., Pullan R.D., Newcombe R.G., Rhodes J., Wilkinson S., Rhodes P., Roberts G., Lawrie B.W., et al. Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease. Gut 35 (1994) 363-368
26. Thomas G.A., Swift G.L., Green J.T., Newcombe R.G., Braniff-Mathews C., Rhodes J., Wilkinson S., Strohmeyer G., and Kreuzpainter G. Controlled trial of antituberculous chemotherapy in Crohn's disease: a five year follow up study. Gut 42 (1998) 497-500
27. Borgaonkar M.R., MacIntosh D.G., and Fardy J.M. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 95 (2000) 725-729
28. Selby W., Pavli P., Crotty B., Florin T., Radford-Smith G., Gibson P., Mitchell B., Connell W., Read R., Merrett M., Ee H., Hetzel D., and Antibiotics in Crohn's Disease Study Group. Two-year combination antibiotic therapy with clarithromycin, rifabutin and clofazimine for Crohn's disease. Gastroenterology 132 (2007) 2313-2319
29. Mitchell I.C., and Turk J.L. Effect of the immune modulating agents cyclophosphamide, methotrexate, hydrocortisone, and cyclosporin A on an animal model of granulomatous bowel disease. Gut 31 (1990) 674-678
30. Shafran S.D., Singer J., Zarowny D.P., Phillips P., Salit I., Walmsley S.L., Fong I.W., Gill M.J., Rachlis A.R., Lalonde R.G., Fanning M.M., and Tsoukas C.M. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med 335 (1996) 377-383
31. Dunne M., Fessel J., Kumar P., Dickenson G., Keiser P., Boulos M., Mogyros M., White Jr. A.C., Cahn P., O'Connor M., Lewi D., Green S., Tilles J., Hicks C., Bissett J., Schneider M.M., and Benner R. A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis 31 (2000) 1245-1252
32. Naik S., and Ruck R. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob Agents Chemother 33 (1989) 1614-1616
33. Borody T.J., Bilkey S., Wettstein A.R., Leis S., Pang G., and Tye S. Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars. Dig Liver Dis (2007)
34. Peyrin-Biroulet L., Chamaillard M., Gonzalez F., Beclin E., Decourcelle C., Antunes L., Gay J., Neut C., Colombel J.F., and Desreumaux P. Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?. Gut 56 (2007) 577-583
35. Neyrolles O., Hernandez-Pando R., Pietri-Rouxel F., Fornes P., Tailleux L., Payan J.A., Pivert E., Bordat Y., Aguilar D., Prevost M.C., Petit C., and Gicquel B. Is adipose tissue a place for Mycobacterium tuberculosis persistence?. PLoS ONE 1 (2006) e43
36. Shin S.J., Wu C.W., Steinberg H., and Talaat A.M. Identification of novel virulence determinants in Mycobacterium paratuberculosis by screening a library of insertional mutants. Infect Immun 74 (2006) 3825-3833
37. Hisamatsu T., Suzuki M., Reinecker H.C., Nadeau W.J., McCormick B.A., and Podolsky D.K. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 124 (2003) 993-1000
38. Wehkamp J., Salzman N.H., Porter E., Nuding S., Weichenthal M., Petras R.E., Shen B., Schaeffeler E., Schwab M., Linzmeier R., Feathers R.W., Chu H., Lima Jr. H., Fellermann K., Ganz T., Stange E.F., and Bevins C.L. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 102 (2005) 18129-18134
39. Bernstein C.N., Wang M.H., Sargent M., Brant S.R., and Collins M.T. Testing the interaction between nod-2 status and serological response to Mycobacterium paratuberculosis in cases of inflammatory bowel disease. J Clin Microbiol 45 (2007) 968-971
40. Duerr R.H., Taylor K.D., Brant S.R., Rioux J.D., Silverberg M.S., Daly M.J., Steinhart A.H., Abraham C., Regueiro M., Griffiths A., Dassopoulos T., Bitton A., Yang H., Targan S., Datta L.W., Kistner E.O., Schumm L.P., Lee A.T., Gregersen P.K., Barmada M.M., Rotter J.I., Nicolae D.L., and Cho J.H. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314 (2006) 1461-1463
41. Happel K.I., Lockhart E.A., Mason C.M., Porretta E., Keoshkerian E., Odden A.R., Nelson S., and Ramsay A.J. Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs. Infect Immun 73 (2005) 5782-5788
42. Verreck F.A., de Boer T., Langenberg D.M., Hoeve M.A., Kramer M., Vaisberg E., Kastelein R., Kolk A., de Waal-Malefyt R., and Ottenhoff T.H. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci U S A 101 (2004) 4560-4565
43. Greenstein R.J., Su L., Haroutunian V., Shahidi A., and Brown S.T. On the action of methotrexate and 6-mercaptopurine on M. avium subspecies paratuberculosis. PLoS ONE 2 (2007) e161
44. Martin H.M., Campbell B.J., Hart C.A., Mpofu C., Nayar M., Singh R., Englyst H., Williams H.F., and Rhodes J.M. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 127 (2004) 80-93
45. Darfeuille-Michaud A., Boudeau J., Bulois P., Neut C., Glasser A.L., Barnich N., Bringer M.A., Swidsinski A., Beaugerie L., and Colombel J.F. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127 (2004) 412-421
46. Swidsinski A., Ladhoff A., Pernthaler A., Swidsinski S., Loening-Baucke V., Ortner M., Weber J., Hoffmann U., Schreiber S., Dietel M., and Lochs H. Mucosal flora in inflammatory bowel disease. Gastroenterology 122 (2002) 44-54
47. Alpern J., Sasaki M., Sitaraman S., Rutherford R., Olejeme H., Cai Q., and Klapproth J. Invasive E. coli strains are increased in Crohn's disease. Gastroenterology 130 (2006) A-362
48. Kotlowski R., Bernstein C.N., Sepehri S., and Krause D.O. High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 56 (2006) 669-675